by divibasicbldev | Nov 25, 2025 | Press Releases
— The ALS Association is the world’s leading funder of amyotrophic lateral sclerosis (ALS) research — — The Hoffman ALS Clinical Trial Awards Program was created to fund early- to mid-stage biomarker-driven clinical trials of novel or...
by divibasicbldev | Nov 24, 2025 | Press Releases
— Zero Treatment Related Adverse Events observed during Cohort 7 (37mg capsules) DLT period – –Cohort 7 Pharmacokinetic (PK) profile continues to demonstrate dose-proportionality and Cmax/Cmin ratio <2. Achieved exposures (AUC) of 6,690...
by divibasicbldev | Nov 21, 2025 | Press Releases
— Tablet PK exposure increases proportionally with an increase in dose — — More favorable PK properties in tablets enable a lower dose to achieve the same exposure as the capsule formulation, with improved predictability and reduced variability...
by divibasicbldev | Nov 20, 2025 | Press Releases
— Evidence of Monotherapy Activity: Partial response observed in a MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation who remains on trial for more than 11 months — — A second MEK-rechallenge 3rd-line melanoma patient with BRAF V600E...
by divibasicbldev | Nov 4, 2025 | Press Releases
Platinum sponsorship of NF Caregivers Symposium reinforces commitment to NF1 communityMIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company...
